Seekingalpha:
- ACADIA Pharmaceuticals (ACAD +8.9%) has recorded the biggest intraday gain since March after Guggenheim raised its rating on the biotech to Buy from Neutral.
- The analyst Yatin Sunejaa has a favorable view on the company’s upcoming Phase 3 topline data read for its Rett syndrome candidate trofinetide scheduled for Q4 2021.
- “Given the limited investor interest in this program, we like the risk-reward heading into the readout,” Sunejaa wrote with the price target of $23 per share of Acadia (NASDAQ:ACAD), implying a premium of ~28.1% to the last close.
- In addition to the Phase II study, “one more successful trial will be sufficient to file an NDA in 2022,” the firm noted, citing the company management.
- In March 2020, Acadia (ACAD) announced that the FDA granted the Rare Pediatric Disease designation to trofinetide in the treatment of Rett syndrome.
Now +12%
Share Price, page-56
-
- There are more pages in this discussion • 10,899 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$20.10 |
Change
-0.620(2.99%) |
Mkt cap ! $2.569B | |||
| Open | High | Low | Value | Volume |
| $20.41 | $20.45 | $19.92 | $5.947M | 296.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 999 | $20.10 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $20.19 | 10 | 1 |
View Market Depth
| Last trade - 16.10pm 25/07/2024 (20 minute delay) ? |
| NEU (ASX) Chart |